Halozyme Therapeutics Inc. Stock
There is an upward development for Halozyme Therapeutics Inc. compared to yesterday, with an increase of €0.78 (1.370%).
With 19 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
With a target price of 70 € there is a positive potential of 20.98% for Halozyme Therapeutics Inc. compared to the current price of 57.86 €.
Our community identified positive and negative aspects for Halozyme Therapeutics Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Halozyme Therapeutics Inc. stock. On the other hand our users think that "Expected dividend yield" could be a problem in the future.
Pros and Cons of Halozyme Therapeutics Inc. in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Halozyme Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc. | 1.370% | 4.009% | 2.625% | 5.625% | -2.594% | 76.118% | 48.840% |
| Ligand Pharmaceuticals | 0.510% | 10.056% | 7.650% | 114.130% | 18.675% | 200.763% | 61.741% |
| United Therapeutics | 0.710% | 0.553% | 4.538% | 95.888% | 14.837% | 135.687% | 188.647% |
| Ionis Pharmaceuticals Inc. | 0.740% | -1.696% | 2.246% | 167.478% | -6.210% | 86.866% | 85.398% |
Comments
Halozyme Therapeutics (NASDAQ:HALO) had its price target raised by analysts at Benchmark Co. from $75.00 to $90.00. They now have a "buy" rating on the stock.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at TD Cowen.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at Benchmark Co..
Show more
Ratings data for HALO provided by MarketBeat
News
2 Under-the-Radar Biotech Stocks Set to Boom in 2026
The biotech sector returned to health in 2025 after years of sickly returns. A key sign of vitality was the SPDR S&P Biotech ETF (NASDAQ: IBB), which rose 27% in 2025, nearly doubling the 16% gain
Halozyme Therapeutics: A 6.3 Rating and a Future Full of Uncertainty
Explore the exciting world of Halozyme Therapeutics (NASDAQ: HALO) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights
The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar.
Over the last three months, the S&P 500 healthcare sector has risen 13%, compared to the broader S&P 500 index's 7% increase.
However, one stock that hasn't matched its sector's returns is Halozyme